CVKD Key Statistics, Chart & Performance
The current stock price of CVKD is 8.17 USD. In the past month the price decreased by -26.46%. In the past year, price decreased by -49.78%.
CVKD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.37 | 1.01T | ||
| JNJ | JOHNSON & JOHNSON | 19.69 | 492.44B | ||
| MRK | MERCK & CO. INC. | 12.55 | 274.34B | ||
| PFE | PFIZER INC | 7.96 | 144.87B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.52 | 113.72B | ||
| ZTS | ZOETIS INC | 20.06 | 56.04B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.77 | 23.19B | ||
| VTRS | VIATRIS INC | 5.48 | 14.70B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.45 | 11.66B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.54B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.53B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.05B |
Related stock screener links
About CVKD
Company Profile
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. The company is headquartered in Ponte Vedra, Florida and currently employs 4 full-time employees. The company went IPO on 2023-01-20. The company has three clinical-stage assets: VLX-1005, a first-in-class Phase 2 12-LOX Inhibitor for patients with HIT; tecarfarin, an oral vitamin K antagonist (VKA) for chronic use in patients with kidney dysfunction or left ventricular assist devices (LVADs), and frunexian, a parenteral small-molecule Factor XIa antagonist for use in acute hospital settings. Its product candidate, tecarfarin, is a late-stage, reversible oral VKA in the same drug class as warfarin, designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Its frunexian is a small molecule fast-on, fast-off parenteral Phase II-ready potent intravenous (IV) Factor XIa inhibitor designed for acute care settings, especially where contact activation of coagulation by medical devices or artificial surfaces plays a significant role.
Company Info
CADRENAL THERAPEUTICS INC
822 A1a North, Suite 306
Ponte Vedra FLORIDA US
Employees: 4
Phone: 19043000701
CADRENAL THERAPEUTICS INC / CVKD FAQ
What does CADRENAL THERAPEUTICS INC do?
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. The company is headquartered in Ponte Vedra, Florida and currently employs 4 full-time employees. The company went IPO on 2023-01-20. The company has three clinical-stage assets: VLX-1005, a first-in-class Phase 2 12-LOX Inhibitor for patients with HIT; tecarfarin, an oral vitamin K antagonist (VKA) for chronic use in patients with kidney dysfunction or left ventricular assist devices (LVADs), and frunexian, a parenteral small-molecule Factor XIa antagonist for use in acute hospital settings. Its product candidate, tecarfarin, is a late-stage, reversible oral VKA in the same drug class as warfarin, designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Its frunexian is a small molecule fast-on, fast-off parenteral Phase II-ready potent intravenous (IV) Factor XIa inhibitor designed for acute care settings, especially where contact activation of coagulation by medical devices or artificial surfaces plays a significant role.
What is the stock price of CADRENAL THERAPEUTICS INC today?
The current stock price of CVKD is 8.17 USD. The price increased by 3.68% in the last trading session.
What is the dividend status of CADRENAL THERAPEUTICS INC?
CVKD does not pay a dividend.
What is the ChartMill technical and fundamental rating of CVKD stock?
CVKD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Who owns CADRENAL THERAPEUTICS INC?
You can find the ownership structure of CADRENAL THERAPEUTICS INC (CVKD) on the Ownership tab.
CVKD Technical Analysis
CVKD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CVKD. CVKD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
CVKD Financial Highlights
Over the last trailing twelve months CVKD reported a non-GAAP Earnings per Share(EPS) of -8.01. The EPS decreased by -19.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -351.94% | ||
| ROE | -525.99% | ||
| Debt/Equity | 0 |
CVKD Forecast & Estimates
7 analysts have analysed CVKD and the average price target is 36.38 USD. This implies a price increase of 345.29% is expected in the next year compared to the current price of 8.17.